Mantomed (Memantine Hydrochloride)

Memantine blocks the NMDA‑type glutamate receptor in a non‑competitive manner, reducing excessive calcium entry into neurons. This limits excitotoxic damage that contributes to the progressive loss of memory and cognition seen in Alzheimer’s disease.

The dosage of Mantomed is determined by the prescribing clinician based on the patient’s condition, renal function, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for memantine in pregnancy and lactation are limited. The product is classified as having an unknown pregnancy category, so it should be used only if the potential benefit justifies the potential risk to the fetus or infant.

To request Mantomed, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mantomed (memantine) is an NMDA‑receptor antagonist, whereas cholinesterase inhibitors such as donepezil act by increasing acetylcholine levels. Memantine is typically used in moderate to severe stages and may be combined with a cholinesterase inhibitor for additive benefit.

Mantomed should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture and direct sunlight to maintain its stability.

Mantomed is taken orally, usually once daily after a gradual titration period as directed by the prescriber. Tablets should be swallowed whole with water and not crushed or chewed unless specifically advised.

Serious risks include seizures, severe allergic reactions such as anaphylaxis, Stevens‑Johnson syndrome, hepatic dysfunction, and cardiac arrhythmias. Patients should seek immediate medical attention if they experience any of these symptoms.

Mantomed is contraindicated in patients with known hypersensitivity to memantine or any of its excipients, and it should be avoided in individuals with severe renal impairment without dose adjustment. Clinicians should also assess suitability in patients with uncontrolled epilepsy or serious cardiac conditions.